115 related articles for article (PubMed ID: 10323057)
1. Accumulation of methotrexate in human tissues following high-dose methotrexate therapy.
Iqbal MP
J Pak Med Assoc; 1998 Nov; 48(11):341-3. PubMed ID: 10323057
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma.
Fujita Y; Nakamura T; Aomori T; Nishiba H; Shinozaki H; Yanagawa T; Takagishi K; Watanabe H; Okada Y; Nakamura K; Horiuchi R; Yamamoto K
J Chemother; 2010 Jun; 22(3):186-90. PubMed ID: 20566424
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacological evaluation and efficacy study of methotrexate-encapsulated polymer-coated layered double hydroxide nanoparticles for possible application in the treatment of osteosarcoma.
Ray S; Saha S; Sa B; Chakraborty J
Drug Deliv Transl Res; 2017 Apr; 7(2):259-275. PubMed ID: 28050892
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
[TBL] [Abstract][Full Text] [Related]
5. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literature.
Bielack SS; Beron G; Winkler K
Cancer; 1997 Aug; 80(3):516-8. PubMed ID: 9241087
[No Abstract] [Full Text] [Related]
6. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma.
Johansson ÅM; Hill N; Perisoglou M; Whelan J; Karlsson MO; Standing JF
Ther Drug Monit; 2011 Dec; 33(6):711-8. PubMed ID: 22105588
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
[TBL] [Abstract][Full Text] [Related]
8. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma.
Mir O; Ropert S; Babinet A; Alexandre J; Larousserie F; Durand JP; Enkaoua E; Anract P; Goldwasser F
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1059-63. PubMed ID: 20155268
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with high-dose methotrexate in osteosarcoma.
Mir O; Ropert S; Goldwasser F
Lancet Oncol; 2008 Dec; 9(12):1198. PubMed ID: 19038767
[No Abstract] [Full Text] [Related]
10. [Tissue concentration of methotrexate in osteosarcoma after high-dose infusion].
Amino K
Nihon Seikeigeka Gakkai Zasshi; 1982 Aug; 56(8):765-76. PubMed ID: 6984057
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate is effective in osteosarcoma so what is the problem?
Cohen IJ
J Pediatr Hematol Oncol; 2009 Dec; 31(12):892-4. PubMed ID: 19887958
[No Abstract] [Full Text] [Related]
12. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
13. Successful rescue by oral cholestyramine of a patient with methotrexate nephrotoxicity: nonrenal excretion of serum methotrexate.
Shinozaki T; Watanabe H; Tomidokoro R; Yamamoto K; Horiuchi R; Takagishi K
Med Pediatr Oncol; 2000 Mar; 34(3):226-8. PubMed ID: 10696135
[No Abstract] [Full Text] [Related]
14. The classic: recent advances in chemotherapy of metastatic osteogenic sarcoma. 1972.
Jaffe N
Clin Orthop Relat Res; 2005 Sep; 438():19-21. PubMed ID: 16131864
[No Abstract] [Full Text] [Related]
15. [Evaluation of severe side effects of high-dose methotrexate in osteosarcoma].
Umeda T; Takada N; Hodaka E; Endoh F; Ishii T
Gan To Kagaku Ryoho; 1984 Feb; 11(2):285-94. PubMed ID: 6582805
[TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate in fibroblastic osteosarcoma.
Chowbay B; Siong KK
Ann Pharmacother; 2001 Dec; 35(12):1669. PubMed ID: 11793640
[No Abstract] [Full Text] [Related]
17. [Individualization of the dosage of high-dose methotrexate by assaying plasma concentration. Therapeutic value in osteogenic sarcoma].
Delepine N; Desbois JC; Delepine G; Cornille H; Astier A; Alkallaf S
Bull Cancer; 1989; 76(8):913-8. PubMed ID: 2620125
[No Abstract] [Full Text] [Related]
18. High-dose methotrexate in osteogenic sarcoma: a 5-year experience.
Jaffe N; Frei E; Watts H; Traggis D
Cancer Treat Rep; 1978 Feb; 62(2):259-64. PubMed ID: 346215
[No Abstract] [Full Text] [Related]
19. Drug-drug interaction between methotrexate and levetiracetam resulting in delayed methotrexate elimination.
Bain E; Birhiray RE; Reeves DJ
Ann Pharmacother; 2014 Feb; 48(2):292-6. PubMed ID: 24259648
[TBL] [Abstract][Full Text] [Related]
20. [A case of subacute transient cerebral dysfunction in a osteosarcoma patient following high-dose methotrexate].
Yamada K; Takahashi M; Yoshida M
Gan To Kagaku Ryoho; 2002 Mar; 29(3):469-72. PubMed ID: 11915742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
